HEOR

Health technology assessments (HTA) to reimburse a new health technology typically encompass an economic analysis. Pharmaceutical manufacturers must demonstrate the clinical and economic evidences of products to gain market access and remain competitive. Economic evidence is often generated by evaluating both costs and outcomes to prove the efficiency of a product. phamax HEOR services generate relevant evidence for products to communicate their value to stakeholders.

phamax HEOR services include:

  • Systematic literature reviews and meta-analysis: Our systematic literature review services answer all the important questions on efficacy, safety, quality of life and resource use. We follow the PRISMA guidelines and work with clients to define the scope of project, submit the protocol, identify databases, and shortlist articles. We critically appraise relevant research and analyse data from studies to answer the clients’ research questions and also perform meta-analysis, when required
  • Patient Reported Outcomes (PRO)

phamax PRO studies provide unique insights into how a therapy can affect a patient. We design studies that enable clients to capture patient perspectives on a disease/treatment under different scenarios – clinical (e.g. cure, survival), humanistic (e.g. role performance, emotional status) and economical (e.g. expenses, saving)

  • Economic evaluations:
  • Cost-effectiveness analysis (CEA)
  • Cost-utility analysis (CUA)
  • Budget-impact analysis (BIA)
  • Burden of disease or Illness/Economic impact analysis

Our models estimate the costs and outcomes of interventions, and compare different interventions impacting the same health effects (usually measured as life years gained) and different health effects (usually measured as utility-based outcome units (QALYs)). HEOR models for economic evaluations are the new normal for favourable reimbursement decisions. Our services demonstrate the cost effectiveness of product vs. the competition to support reimbursement submissions and highlight the incremental effectiveness of products at multiple price points.

  • Synthesis of systematically-derived data for clinical and economic analyses
  • Support reimbursement decisions by evaluating the clinical and economic impact of products
  • Understand the impact of technologies in a real-life context and comprehend the needs and preferences of patients
  • Understand the quality of life aspects and measure the burden of the disease by incorporating all the costs associated with the disease/intervention
  • Evaluate the long-term effects (length and quality of life) of an intervention on health outcomes and ease the comparison of costs and outcomes of different interventions
  • Determine the impact of implementing or adopting a particular technology on a designated budget